Back to Search
Start Over
Pneumocystis jirovecii pneumonia in people living with HIV: a review.
- Source :
-
Clinical microbiology reviews [Clin Microbiol Rev] 2024 Mar 14; Vol. 37 (1), pp. e0010122. Date of Electronic Publication: 2024 Jan 18. - Publication Year :
- 2024
-
Abstract
- Pneumocystis jirovecii is a ubiquitous opportunistic fungus that can cause life-threatening pneumonia. People with HIV (PWH) who have low CD4 counts are one of the populations at the greatest risk of Pneumocystis jirovecii pneumonia (PCP). While guidelines have approached the diagnosis, prophylaxis, and management of PCP, the numerous studies of PCP in PWH are dominated by the 1980s and 1990s. As such, most studies have included younger male populations, despite PCP affecting both sexes and a broad age range. Many studies have been small and observational in nature, with an overall lack of randomized controlled trials. In many jurisdictions, and especially in low- and middle-income countries, the diagnosis can be challenging due to lack of access to advanced and/or invasive diagnostics. Worldwide, most patients will be treated with 21 days of high-dose trimethoprim sulfamethoxazole, although both the dose and the duration are primarily based on historical practice. Whether treatment with a lower dose is as effective and less toxic is gaining interest based on observational studies. Similarly, a 21-day tapering regimen of prednisone is used for patients with more severe disease, yet other doses, other steroids, or shorter durations of treatment with corticosteroids have not been evaluated. Now with the widespread availability of antiretroviral therapy, improved and less invasive PCP diagnostic techniques, and interest in novel treatment strategies, this review consolidates the scientific body of literature on the diagnosis and management of PCP in PWH, as well as identifies areas in need of more study and thoughtfully designed clinical trials.<br />Competing Interests: G.B.-L., T.C.L., T.B., Z.N.S., M.S., and E.G.M. are co-investigators on a proposal for a PCP treatment platform trial for people with and without HIV. T.B. has been the principal investigator of clinical trials sponsored by Shionogi Pharmaceuticals, Atea Pharmaceuticals, and Astra Zeneca Pharmaceuticals; he is currently recruiting to a clinical trial, sponsored by Mundpharma, of rezafungin for PCP. T.B. did not contribute to the rezafungin or echinocandin sections.
- Subjects :
- Female
Humans
Male
Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use
Trimethoprim, Sulfamethoxazole Drug Combination pharmacology
Pneumonia, Pneumocystis diagnosis
Pneumonia, Pneumocystis drug therapy
Pneumonia, Pneumocystis prevention & control
Pneumocystis carinii
HIV Infections complications
HIV Infections drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1098-6618
- Volume :
- 37
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Clinical microbiology reviews
- Publication Type :
- Academic Journal
- Accession number :
- 38235979
- Full Text :
- https://doi.org/10.1128/cmr.00101-22